Health Canada OKs Using Ferriprox for Iron Overload

Health Canada has expanded its approval of Chiesi Global Rare Diseases’ iron-binding oral treatment Ferriprox (deferiprone) to patients who have blood transfusion-induced iron overload due to sickle cell disease (SCD) or other anemias.

The decision comes about five months after the U.S. Food and Drug Administration (FDA) approved Ferriprox for the same indication in the U.S. and one month after its approval in Brazil.

The therapy was approved in Canada previously for people with thalassemia major, another inherited blood disorder, who were experiencing iron overload when treatment with current iron-binding, or iron-chelating, agents was ineffective.

“We are very pleased that Health Canada recognizes and further validates the extensive clinical data and track record associated with Ferriprox to make this therapy available to more rare disease patients in the region,” Giacomo Chiesi, head of Chiesi Global Rare Diseases, said in a press release.